ABL1

Across TCGA pan-cancer cohorts, ABL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABL1 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ABL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ABL1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ABL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.259	1.000	.014	12	view →
PDAC	OS	Quartile	All	0.493	0.766	.021	11	view →
LUAD	OS	Tertile	All	1.000	0.928	.018	10	view →
LSCC	OS	Tertile	All	0.911	1.000	.025	7	view →
CCRCC	OS	Median	All	0.926	0.757	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABL1–HNSC (OS)

Open the HNSC breakdown →